Physician profile
Christopher A Pendola
NPI 1013018431
$344,070.85
in general payments reported to CMS, 2019-2025
36 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $102K · 2021: $86K · 2022: $60K · 2023: $8,737 · 2024: $30K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Honoraria: $19K · Food and Beverage: $3,940 · Consulting Fee: $2,808 · Travel and Lodging: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,912.50 |
| Honoraria | $19,210.00 |
| Food and Beverage | $3,940.49 |
| Consulting Fee | $2,807.50 |
| Travel and Lodging | $566.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $161,118.00 | 2021-2025 | |
| Allergan, INC. | $83,703.61 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $38,937.85 | 2019-2023 | Ajovy |
| Genzyme Corporation | $35,213.03 | 2019-2025 | |
| Lundbeck LLC | $23,269.64 | 2023-2025 | Vyepti |
| Ucb, INC. | $785.60 | 2021-2025 | Briviact, Nayzilam |
| Biohaven Pharmaceuticals, INC. | $132.69 | 2021 | |
| Genentech USA, INC. | $125.05 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Djo, LLC | $50.04 | 2021-2025 | Cmf |
| Pacira Pharmaceuticals Incorporated | $49.86 | 2024 | Zilretta, Iovera, Exparel |
| Amgen INC. | $48.42 | 2019-2023 | Aimovig |
| Lilly USA, LLC | $39.40 | 2023-2024 | Emgality, Reyvow, Amyvid |
| Abbott Laboratories | $35.44 | 2021-2025 | Eterna |
| Mdd US Operations, LLC | $34.69 | 2024 | Gocovri |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $32.40 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Upsher-Smith Laboratories LLC | $29.41 | 2022 | |
| Pacira Therapeutics, INC. | $29.01 | 2020-2021 | |
| Ethicon US, LLC | $28.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.14 | 2025 | |
| Si-Bone, INC. | $23.16 | 2025 | |
| Vericel Corporation | $23.05 | 2024 | Maci |
| Stryker Corporation | $21.59 | 2024 | Infinity Adaptis |
| Argenx US, INC. | $21.28 | 2024 | Vyvgart |
| Amylyx Pharmaceuticals, INC. | $16.72 | 2023 | Relyvrio |
| Kerecis Limited | $16.29 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Otsuka America Pharmaceutical, INC. | $16.07 | 2023 | Nuedexta |
| Endo USA, INC. | $15.67 | 2025 | Xiaflex |
| Nevro Corp. | $15.57 | 2024 | Senza |
| Linvatec Corporation | $15.01 | 2023 | Biobrace 23mm, Linvatec Extremities |
| Assertio Therapeutics, INC. | $14.76 | 2019 | |
| Endo Pharmaceuticals INC. | $14.55 | 2021 | |
| Banner Life Sciences, LLC | $12.97 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.74 | 2022 | |
| Impel Pharmaceuticals INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pendola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.